×
About 1,815 results

ALLMedicine™ Cardiovascular Risk Reduction Center

Research & Reviews  821 results

Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies.
https://doi.org/10.1161/JAHA.120.016506
Journal of the American Heart Association; Khan I, Peterson ED et. al.

Jul 28th, 2020 - Background With the availability of new lipid-lowering therapy options, there is a need to compare the expected clinical benefit of different treatment strategies in different patient populations and over various time frames. We aimed to develop a...

Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of random...
https://doi.org/10.1002/clc.23437
Clinical Cardiology REFERENCES; Ferrières J, Bataille V et. al.

Jul 27th, 2020 - The reduction of cardiovascular events with icosapent ethyl-intervention trial (REDUCE-IT) trial revealed robust atherosclerotic cardiovascular risk reduction with a strategy comprising high-dose omega-3 icosapent ethyl vs placebo in statin-treate...

Beginning with the End in Mind - The Case for Primordial and Primary Cardiovascular Pre...
https://doi.org/10.1016/j.cjca.2020.07.002
The Canadian Journal of Cardiology; Patel SS, Daniels SR

Jul 12th, 2020 - Cardiovascular disease (CVD) remains the leading cause of death worldwide. While there is little direct evidence that ties the presence of risk factors in childhood with adult cardiovascular disease, there are multiple indirect lines of evidence t...

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results ...
https://doi.org/10.1111/dom.14140
Diabetes, Obesity & Metabolism; Verma S, Bain SC et. al.

Jul 8th, 2020 - The randomized, double-blind cardiovascular outcomes trials LEADER (NCT01179048) and SUSTAIN 6 (NCT01720446) demonstrated cardiovascular risk reduction in patients with type 2 diabetes treated with liraglutide and semaglutide, respectively, compar...

Lipid management for cardiovascular risk reduction in type 1 diabetes.
https://doi.org/10.1097/MED.0000000000000551
Current Opinion in Endocrinology, Diabetes, and Obesity; Tell S, Nadeau KJ et. al.

Jul 3rd, 2020 - To review the recent evidence for lipid management in type 1 diabetes (T1D) for cardiovascular risk reduction. Individuals with T1D are at increased risk for cardiovascular morbidity and mortality, with atherosclerosis beginning as early as adoles...

see more →

Guidelines  53 results

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
http://www.onlinejacc.org/content/early/2019/03/07/j.jacc.2019.03.010
Journal of the American College of Cardiology;

Mar 16th, 2019 - Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) outcomes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally (S1- 1–S1-3). In the United States, it is also the le...

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext

Feb 1st, 2019 - Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large sta...

Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events
https://jamanetwork.com/journals/jama/article-abstract/2721178
Zheng,S.,et al

Jan 21st, 2019 - Question: What is the association of aspirin use with cardiovascular events and bleeding events in individuals without cardiovascular disease? Findings: In this meta-analysis of 13 trials with 164 225 participants without cardiovascular disease, a...

Evidence of CV benefits of Mediterranean diet growing
https://www.healio.com/cardiology/chd-prevention/news/online/%7B51d6ca5b-5a70-4e7e-ae7b-84b411d0fd62%7D/evidence-of-cv-benefits-of-mediterranean-diet-growing

Jan 5th, 2019 - After the holidays, often as part of a New Year’s resolution, it is common for people to think about changing to a healthier diet. One option is the Mediterranean diet, which was recently named by U.S. News & World Report as the top overall diet, ...

Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
http://care.diabetesjournals.org/content/42/Supplement_1/S124

Dec 17th, 2018 - Chronic kidney disease (CKD) is diagnosed by the persistent presence of elevated urinary albumin excretion (albuminuria), low estimated glomerular filtration rate (eGFR), or other manifestations of kidney damage (1,2). In this section, the focus w...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  881 results

Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies.
https://doi.org/10.1161/JAHA.120.016506
Journal of the American Heart Association; Khan I, Peterson ED et. al.

Jul 28th, 2020 - Background With the availability of new lipid-lowering therapy options, there is a need to compare the expected clinical benefit of different treatment strategies in different patient populations and over various time frames. We aimed to develop a...

Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of random...
https://doi.org/10.1002/clc.23437
Clinical Cardiology REFERENCES; Ferrières J, Bataille V et. al.

Jul 27th, 2020 - The reduction of cardiovascular events with icosapent ethyl-intervention trial (REDUCE-IT) trial revealed robust atherosclerotic cardiovascular risk reduction with a strategy comprising high-dose omega-3 icosapent ethyl vs placebo in statin-treate...

Beginning with the End in Mind - The Case for Primordial and Primary Cardiovascular Pre...
https://doi.org/10.1016/j.cjca.2020.07.002
The Canadian Journal of Cardiology; Patel SS, Daniels SR

Jul 12th, 2020 - Cardiovascular disease (CVD) remains the leading cause of death worldwide. While there is little direct evidence that ties the presence of risk factors in childhood with adult cardiovascular disease, there are multiple indirect lines of evidence t...

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results ...
https://doi.org/10.1111/dom.14140
Diabetes, Obesity & Metabolism; Verma S, Bain SC et. al.

Jul 8th, 2020 - The randomized, double-blind cardiovascular outcomes trials LEADER (NCT01179048) and SUSTAIN 6 (NCT01720446) demonstrated cardiovascular risk reduction in patients with type 2 diabetes treated with liraglutide and semaglutide, respectively, compar...

Lipid management for cardiovascular risk reduction in type 1 diabetes.
https://doi.org/10.1097/MED.0000000000000551
Current Opinion in Endocrinology, Diabetes, and Obesity; Tell S, Nadeau KJ et. al.

Jul 3rd, 2020 - To review the recent evidence for lipid management in type 1 diabetes (T1D) for cardiovascular risk reduction. Individuals with T1D are at increased risk for cardiovascular morbidity and mortality, with atherosclerosis beginning as early as adoles...

see more →

News  57 results

Icosapent ethyl approved for cardiovascular risk reduction
https://www.mdedge.com/emergencymedicine/article/214314/lipid-disorders/icosapent-ethyl-approved-cardiovascular-risk?channel=39313
Catherine Hackett

Dec 13th, 2019 - Icosapent ethyl (Vascepa) has gained an indication from the Food and Drug Administration for reduction of cardiovascular events in patients with high triglycerides who are at high risk for cardiovascular events. Olivier Le Moal/Getty Images It is.

Do women with diabetes need more CVD risk reduction than men?
https://www.mdedge.com/familymedicine/article/214212/diabetes/do-women-diabetes-need-more-cvd-risk-reduction-men/page/0/2?channel=39313
MDedge Endocrinology;

Dec 12th, 2019 - So then, “why is there the view that women with type 2 diabetes need more aggressive cardiovascular risk reduction than men with diabetes? “It probably comes back to confusion based on absolute risk versus a comparison of relative risk within each.

Starting Statin in Childhood Protects FH Hearts
https://www.medpagetoday.com/cardiology/dyslipidemia/82774

Oct 16th, 2019 - Statin use started in childhood for familial hypercholesterolemia (FH) kept atherosclerotic plaque levels normal and was associated with better outcomes in adulthood, long-term follow-up of a clinical trial cohort showed. Mean progression of carot...

Older patients who stop statins may be increasing their cardiovascular risk
https://www.mdedge.com/fedprac/article/205840/lipid-disorders/older-patients-who-stop-statins-may-be-increasing-their?channel=112
Steve Cimino

Aug 2nd, 2019 - Discontinuing statins was associated with an increased risk of hospital admission for a cardiovascular event, according to a study of elderly French patients with no history of heart disease. RogerAshford/Thinkstock “The results of this study sugg.

FDA grants Priority Review to Vascepa for cardiovascular risk reduction
https://www.mdedge.com/cardiology/article/201888/lipid-disorders/fda-grants-priority-review-vascepa-cardiovascular-risk?channel=193
Lucas Franki

May 30th, 2019 - The Food and Drug Administration has granted a Priority Review to the supplemental new drug application for icosapent ethyl (Vascepa). Wikimedia Commons/FitzColinGerald/Creative Commons License If approved, Vascepa – which is produced by Amarin –.

see more →